

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

Puja K. Mehta and Kathy K. Griendling

Division of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia

Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *Am J Physiol Cell Physiol* 292: C82–C97, 2007. First published July 26, 2006; doi:10.1152/ajpcell.00287.2006.—The renin-angiotensin system is a central component of the physiological and pathological responses of cardiovascular system. Its primary effector hormone, angiotensin II (ANG II), not only mediates immediate physiological effects of vasoconstriction and blood pressure regulation, but is also implicated in inflammation, endothelial dysfunction, atherosclerosis, hypertension, and congestive heart failure. The myriad effects of ANG II depend on time (acute vs. chronic) and on the cells/tissues upon which it acts. In addition to inducing G protein- and non-G protein-related signaling pathways, ANG II, via AT₁ receptors, carries out its functions via MAP kinases (ERK 1/2, JNK, p38MAPK), receptor tyrosine kinases [PDGF, EGFR, insulin receptor], and nonreceptor tyrosine kinases [Src, JAK/STAT, focal adhesion kinase (FAK)]. AT₁R-mediated NAD(P)H oxidase activation leads to generation of reactive oxygen species, widely implicated in vascular inflammation and fibrosis. ANG II also promotes the association of scaffolding proteins, such as paxillin, talin, and p130Cas, leading to focal adhesion and extracellular matrix formation. These signaling cascades lead to contraction, smooth muscle cell growth, hypertrophy, and cell migration, events that contribute to normal vascular function, and to disease progression. This review focuses on the structure and function of AT₁ receptors and the major signaling mechanisms by which angiotensin influences cardiovascular physiology and pathology.

vascular smooth muscle; NAD(P)H oxidase; tyrosine and nontyrosine receptor kinases; endothelial dysfunction; vascular disease

THE RENIN-ANGIOTENSIN SYSTEM (RAS) plays a vital role in regulating the physiological processes of the cardiovascular system. Not only does it function as an endocrine system, but it also serves local paracrine and autocrine functions in tissues and organs. The primary effector molecule of this system, angiotensin II (ANG II), has emerged as a critical hormone that affects the function of virtually all organs, including heart, kidney, vasculature, and brain, and it has both beneficial and pathological effects. Acute stimulation with ANG II regulates salt/water homeostasis and vasoconstriction, modulating blood pressure, while chronic stimulation promotes hyperplasia and hypertrophy of vascular smooth muscle cells (VSMCs) (53, 216). In addition, long-term exposure to ANG II also plays a vital role in cardiac hypertrophy and remodeling, in-stent restenosis, reduced fibrinolysis, and renal fibrosis.

Given its diverse range of functions and its potency in affecting cardiovascular physiology, it becomes imperative to understand the characteristics of ANG II receptors and to investigate mechanisms of ANG II-induced signal transduction. Studying the varied roles of ANG II is also of tremendous importance given the beneficial effects of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) in reducing morbidity and mortality in diabetes,

hypertension, atherosclerosis, heart failure, and stroke (69, 77, 168, 220). This review focuses on the structural and functional characteristics of ANG II receptors, the major ANG II-induced cell signaling cascades, and their role in cardiovascular physiology and pathology.

THE RENIN-ANGIOTENSIN SYSTEM

The mechanisms controlling the formation and degradation of ANG II are important in determining its final physiological effect. An octapeptide, ANG II is formed from enzymatic cleavage of angiotensinogen to angiotensin I (ANG I) by the aspartyl protease renin, with subsequent conversion of ANG I to ANG II by angiotensin converting enzyme (ACE). A recently identified carboxypeptidase, ACE2, cleaves one amino acid from either ANG I or ANG II (29), decreasing ANG II levels and increasing the metabolite Ang 1–7, which has vasodilator properties. Thus the balance between ACE and ACE2 is an important factor controlling ANG II levels (32). Even though ACE is the primary enzyme leading to ANG II generation, in the heart the majority of ANG I is converted by chymase (213). Nguyen and colleagues (130) have recently shown that activation of the renin receptor also increases the conversion of angiotensinogen to ANG I, with resultant activation of mitogen-activated protein kinases (MAPKs); interestingly, a high level of renin receptor mRNA is present in the heart and renin receptors have been detected in the subendothelium of coronary and renal arteries. The tissue-specific

Address for reprint requests and other correspondence: K. K. Griendling, Emory Univ., Division of Cardiology, 319 WMB, 1639 Pierce Dr., Atlanta, GA 30322 (e-mail: kgriend@emory.edu).

effect of increased ANG II levels and enhanced RAS activity depends on the cellular expression and activation of AT₁Rs, critical receptors in cardiovascular and renal pathophysiology.

AT₁ RECEPTORS

Structural Characteristics

Most of the known physiological effects of ANG II are mediated by angiotensin type 1 receptors (AT₁Rs), which are widely distributed in all organs, including liver, adrenals, brain, lung, kidney, heart, and vasculature. Composed of 359 amino acids, the AT₁R (40 kDa) belongs to the seven-membrane superfamily of G protein-coupled receptors. The human AT₁R gene has been mapped to chromosome 3. In rats, two isoforms that share 95% amino acid sequence identity have been identified: the AT_{1A}R on chromosome 17 and the AT_{1B}R on chromosome 2 (61). Functionally and pharmacologically, the two receptor subtypes are indistinguishable (52); however, in vivo experiments show that the AT_{1A}R isoform may be more important than AT_{1B}R in regulation of blood pressure (25). The extracellular domain of the receptor is characterized by three glycosylation sites, and mutation of these sites has no effect on agonist binding. G protein interactions occur on the transmembrane domain at the NH₂ terminus and the first and the third extracellular loops (23). Along with several residues located on the extracellular region of the receptor, four cysteine residues of AT₁R form disulfide bridges and are essential for ANG II binding (143). Similar to other receptors (muscarinic and adrenergic), the AT₁ receptor's cytoplasmic tail contains many serine/threonine residues, which are phosphorylated by G protein receptor kinases or GRKs (discussed later). Modifications within these functional sites may be responsible for the altered receptor function in cardiovascular disease.

Polymorphisms

Genetic variations in the RAS cascade have been associated with cardiovascular disease. Evidence suggests that genetics play an important role in interindividual differences in response to ANG II. Recent advances in gene mapping have identified single nucleotide polymorphisms (SNPs) of the AT₁R gene that have been linked to an increased development of cardiovascular risk factors. The A1166C polymorphism of the AT₁R gene has been implicated in hypertension (21), increased aortic stiffness (14), and myocardial infarction (16). One study in hypertensive patients on a high-salt diet found an association between A1166C polymorphisms and increased ANG II sensitivity (179). In isolated human arteries, A1166C is associated with enhanced vasoconstriction by ANG II (207). However, other studies have not found clear associations, and overall the importance of SNPs in hypertension remains controversial (61, 116). The role of AT₁R polymorphisms has also been evaluated in hyperlipidemia. In patients with familial hypercholesterolemia, a polygenic genetic condition in which there is a decrease in the number of LDL receptors, the A1166C SNP may increase the risk of coronary heart disease (212).

Oligomerization

Not only do AT₁Rs independently regulate many cellular functions, but data shows that they also undergo homo and

hetero oligomerization with many other receptors, including bradykinin B₂ receptors, β₂ adrenergic receptors, and dopamine D₂ receptors (1, 2, 222). Recently, it has been shown that AT₂Rs directly bind to AT₁Rs, interfering with AT₁R function; interestingly, the inhibition of AT₁R signaling by AT₂R is independent of agonist-induced activation of AT₂R (1). Hansen and colleagues (67) showed that AT₁R homodimerization is constitutive (not affected by receptor agonists/antagonists) and occurs prior to its expression on cell membrane. Bradykinin B₂ receptors potentiate AT₁R signaling; during pregnancy-induced hypertension, increased AT₁R/B₂ heterodimers enhance the vasoconstrictive effects of ANG II. Evidence also exists of direct interaction between the β-adrenergic receptors and AT₁Rs (2, 11). Valsartan, an angiotensin receptor blocker, is able to simultaneously block signaling of both AT₁Rs and β-adrenergic receptors in mice (11). Furthermore, beta-blockers have also been shown to interfere with ANG II signaling in heart failure and have become a mainstay of therapy in patients with chronic heart failure (11, 56). The mechanisms and functional consequences of AT₁R oligomerization remain elusive, but may provide a way to expand our pharmacologic armamentarium against vascular disease.

AT₁R Regulation

The AT₁R serves as a control point for regulating the ultimate effects of ANG II on its target tissue. Thus, it becomes necessary to understand the mechanisms that control AT₁R density on the cell membrane. Acutely, increased levels of ANG II lead to an increased level of AT₁R activation; however, chronic exposure to ANG II downregulates its own receptors (60, 102, 192). Not only is AT₁R expression under tight negative feedback control from its agonist, but in VSMCs, numerous other growth factors and cytokines either upregulate or downregulate receptor expression (see Table 1).

AT₁R regulation can provide a mechanistic link between hypertension and various disorders such as hyperlipidemia and hyperinsulinemia. LDL has been shown to upregulate the AT₁Rs via posttranscriptional mRNA stabilization. AT₁Rs are upregulated in platelets, and ANG II-induced vasoconstriction is enhanced in hypercholesterolemic men (132, 134). Emerging data suggests that the pleiotropic actions of statins (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors) may be explained in part by their ability to downregulate AT₁R density and function, thus decreasing ANG II signal transduction. In addition, insulin upregulates AT₁R gene expression by

Table 1. Regulation of AT₁Rs in the cardiovascular system

Cell Type	Agonists That Upregulate	Agonists That Downregulate
VSMCs	LDL (132) Insulin (184) Progesterone (135) Erythropoietin (12)	Angiotensin II (65) Interferon-γ (78) Estrogen (135) Vitamin A (185) HMG CoA reductase inhibitors (75) Epidermal growth factor (66, 199) Platelet-derived growth factor (133) Thyroid hormone (49) Nitric oxide (76) Forskolin (62)

References are given in parentheses. VSMCs, vascular smooth muscle cells; HMG, 3-hydroxy-3-methyl-glutaryl.

post-transcriptional mRNA stabilization, providing molecular evidence of an association between hyperinsulinemia and hypertension (131).

Desensitization and Internalization

Similar to many agonist-receptor systems, the effect of ANG II on its target tissues appears to be transient; that is, after stimulation with this hormone, tissue is desensitized to further agonism. Experiments performed over a decade ago showed that AT₁Rs are endocytosed within 10 min of its activation (60). Approximately 25% of the internalized receptors are recycled back to plasma membrane, and the remainder are degraded in lysosomes (60, 65). Numerous proteins appear to play a role in the highly coordinated process of endocytic recycling, including β -arrestins, G protein-mediated phospholipase D₂, and the Rab family of GTPases (37).

One of the mechanisms believed to play a part in receptor desensitization involves receptor phosphorylation. On the cytoplasmic surface of the AT₁R, several serine/threonine phosphorylation sites serve as a substrate for GRKs, which mediate receptor desensitization by uncoupling the receptor from its activated G protein. In HEK-293 cells, GRK-2, GRK-3, and GRK-5 have been shown to phosphorylate the rat AT₁R, preventing activation of protein kinase C (PKC) (145). Furthermore, in rat VSMCs, ANG II has also been shown to phosphorylate AT₁Rs (88). Once the COOH terminus of AT₁R is phosphorylated by GRK 2/3, the receptor is internalized into specialized, clathrin-coated pits (50, 105). This process is mediated by β -arrestins, a group of multifunctional proteins that not only initiate receptor internalization, but also serve as scaffolds to link downstream signaling molecules to G protein-coupled receptors (92, 105). Interestingly, at physiologic concentrations of ANG II, internalization of AT₁Rs into clathrin-coated pits is β -arrestin dependent, but when AT₁Rs are saturated with ANG II, their internalization is β -arrestin independent (178). Once endocytosed, the receptor induces specific cell signaling pathways. For example, when AT₁Rs are phosphorylated by GRK 5/6, β -arrestin-mediated ERK signaling is activated, independent of G protein signaling (92). Defects in the desensitization process have been implicated in vascular disease; indeed, ANG II-induced hypertensive rats appear to overexpress GRK-5, altering ANG II responsiveness (82).

More recently, there is strong evidence that AT₁R internalization also occurs via noncoated pits. After agonist binding, the AT₁R moves to noncoated specialized microdomains called caveolae, associated with caveolin (83). Signaling molecules such as EGFR and Src are co-localized with caveolin-1 (Cav-1) found in these specialized microdomains (58, 224). In VSMCs, ANG II promotes the association of AT₁R with Cav-1, and enables trafficking into caveolin-rich domains. The association of Cav-1 with AT₁R appears vital in Rac 1 activation (224). Recently, it has also been demonstrated that when stimulated by ANG II, c-Src immediately activates c-Abl (205); activation of c-Abl allows for translocation of Rac 1 to lipid rafts, which in turn promotes NAD(P)H-dependent ANG II signaling, causing VSMC hypertrophy (224).

Heterologous regulation of AT₁R and its endocytic recycling is only possible if the cellular trafficking and recycling systems tightly regulate and coordinate the transport of AT₁Rs to the cell membrane. The Rab family of proteins are Ras-related

GTPases that regulate intercellular vesicular transport. Specifically, Rab 1 has been associated with transport of AT₁R from endoplasmic reticulum to Golgi to cell surface (214). Recent studies report that Rab 5 contributes to the trafficking and fusion of clathrin-coated vesicles with early endosomes (178). In COS-7 cells, the interaction of Rab5a with the COOH terminus of AT₁R promotes its transport to enlarged endosomes (170). Compartmentalization of AT₁R into these microdomains may be necessary for efficient signaling, considering the spatial relationships of different proteins.

AT₂ RECEPTORS

Even though most of the vasoactive effects of ANG II occur via AT₁R, AT₂R have been shown to exert anti-proliferative and pro-apoptotic changes in VSMCs, mainly by antagonizing AT₁R (61). Similar to the AT₁R, the AT₂R (MW 41 kDa) is a seven transmembrane domain receptor, but is only 34% identical to AT₁R (127). Consisting of 363 amino acids, AT₂R is highly expressed in fetal tissue, including fetal aorta, gastrointestinal mesenchyme, connective tissue, skeletal system, brain, and adrenal medulla. AT₂R expression declines after birth, suggesting that it may play an important role in fetal development (175), and can be induced later in adult life under pathological conditions. Autopsy results of nonfailing human hearts show that the heart has approximately 50% AT₂R; in chronic heart failure, AT₁R are downregulated compared with AT₂R (197). AT₂R are also expressed at low levels in kidney, lung, and liver, but their exact role in carrying out the functions of ANG II remains undetermined. Studies have shown that AT₂R antagonizes AT₁R by inhibiting its signaling pathways via activation of tyrosine or serine/threonine phosphatases (13, 128). However, D'Amore and colleagues (31) recently found that AT₂R cause hypertrophy in cardiomyocytes, independent of ANG II, and not block AT₁R-mediated hypertrophy. This hypertrophic response is mediated by direct binding of the transcription factor PLZF (promyelocytic leukemia zinc finger protein) to the tail of the AT₂R, leading to nuclear translocation and enhanced transcription of the p85 subunit of phosphatidylinositol 3-kinase (PI3K) (101, 173). In contrast, consistent with its antagonistic effects on AT₁R, in a mouse model of inflammation-dependent vascular disease, deletion of AT₂R enhanced neointimal formation and inflammation (23). Furthermore, dimerization of the two receptor types also causes an interruption in AT₁R signaling (1). The exact role and the extent to which AT₂R play a role in pathology (or are a consequence of pathology) is unclear as various studies have produced conflicting results.

ANG II SIGNALING PATHWAYS

Once ANG II binds to the AT₁R, it activates a series of signaling cascades, which in turn regulate the various physiological effects of ANG II. Traditionally, the pathways induced by ANG II have been divided into two classifications: G protein- and non-G protein-related signaling; however, these distinctions are becoming blurred as more data emerge. One well established mechanism by which ANG II signaling occurs involves the classic G protein-mediated pathways. In addition to activating the G protein-dependent pathways, ANG II also cross-talks with several tyrosine kinases via AT₁R, including receptor tyrosine kinases [EGFR, PDGF, insulin receptor and

nonreceptor tyrosine kinases [c-Src family kinases, Ca²⁺-dependent proline-rich tyrosine kinase 2 (Pyk2), focal adhesion kinase (FAK) and Janus kinases (JAK)]. In addition, many of ANG II's pathologic effects in the vasculature occur via activation of NAD(P)H oxidases and generation of reactive oxygen species (ROS) (63). AT₁R also activates serine/threonine kinases such as PKC and MAPKs [including ERK1/2, p38MAPK, and c-Jun NH₂-terminal kinase (JNK)] that are implicated in cell growth and hypertrophy. The induction of the above mentioned pathways is tightly regulated; in patients with overstimulated RAS or enhanced responsiveness to ANG II, these pathways may initiate and propagate pathological events promoting vascular disease (73, 183).

The temporal and spatial patterns of signaling pathway activation are the most likely determinants of a particular functional response. Multiple studies show that the activation of different pathways by ANG II is time dependent. For example, activation of the G protein-dependent pathway and generation of IP₃ occurs in seconds, while MAP kinase and JAK/STAT activation occurs in minutes to hours after initial activation of AT₁R (118, 169). Furthermore, differences in receptor/ligand affinity, alteration in trafficking patterns, AT₁R structural modifications, and the local tissue environment all appear to play a role in the ultimate effects of ANG II signaling.

G Protein-Coupled Pathways

One of the major acute functions of ANG II is vasoconstriction, which is mediated by "classical" G protein-dependent signaling pathways (see Fig. 1). Evidence shows that when activated by an agonist, AT₁Rs couple to G_{αq/11}, G_{α12/13}, and G_{βγ} complexes (202), which activate downstream effectors including phospholipase C (PLC), phospholipase A₂ (PLA₂), and phospholipase D (PLD) (200). Activation of PLC produces inositol-1,4,5-triphosphate (IP₃) and diacylglycerol (DAG) within seconds. IP₃ binds to its receptor on sarcoplasmic reticulum, opening a channel that allows calcium efflux into

the cytoplasm. Ca²⁺ binds to calmodulin and activates myosin light chain kinase (MLCK), which phosphorylates the myosin light chain and enhances the interaction between actin and myosin, causing smooth muscle cell contraction (217). To counter-regulate MLCK, cells have myosin light chain phosphatase (MLCP), which is inhibited by Rho kinase, leading to sustained contraction (85, 177). Evidence shows that inhibition of Rho kinase blocks Ca²⁺-induced sensitization in smooth muscle cells (198). Furthermore, ANG II has also been shown to increase phosphorylation of CPI-17 (a MLCP inhibitor) via PKC (171). In addition, DAG activates PKC, which not only serves to increase the pH during cell contraction by phosphorylating the Na⁺/H⁺ pump (206), but also participates as an effector in the Ras/Raf/MEK/ERK pathway. These downstream molecules contribute to the vasoconstrictive properties of AT₁R activation and lead to ANG II's growth promoting effects. ANG II-induced G protein signaling may also explain the relationship between hyperglycemia and vascular dysfunction (55, 180). In VSMCs cultured from hyperglycemic rats, PKC inhibition attenuates ANG II-mediated growth and migration (219), both of which contribute to vascular lesion formation.

Agonist-AT₁R interaction also leads to PLD activation, resulting in hydrolysis of phosphatidylcholine (PC) to choline and phosphatidic acid (PA). PA is rapidly converted to DAG, leading to sustained PKC activation, and sustained muscle contraction. The PLC/PLD pathways causing muscle contraction are augmented in hypertensive rats compared with controls, suggesting that alterations in the G protein-activated second messengers may play a role in the pathogenesis of hypertension (9, 194).

ANG II has been shown to phosphorylate and activate PLA₂, which leads to production of arachidonic acid (AA) and its metabolites. The derivatives of AA function in maintaining vascular tone and in VSMC NAD(P)H oxidation (63). The cyclooxygenase-derived prostaglandins, such as PGI₂ and PGE₂ are vasodilatory, and are counteracted by PGH₂ and




Fig. 1. The role of ANG II in vascular smooth muscle cell contraction. Via G protein signaling, AT₁Rs are able to mobilize Ca²⁺ from the sarcoplasmic reticulum, and promote the interaction of actin and myosin filaments to allow for contraction and migration of cells. ANG II-induced arachidonic acid metabolism via phospholipase A₂ also maintains a balance between vasoconstriction and vasodilation in various vascular beds. One of the major pathways activated by G protein interaction with AT₁R leads to the activation of PKC and the ERK pathway, implicated in sustenance of contraction as well as cellular growth. PC, phosphatidylcholine; PLD, phospholipase D; PA, phosphatidic acid; PIP₂, phosphatidylinositol bisphosphate; PLC, phospholipase C; PKC, protein kinase C; DAG, diacylglycerol; IP₃, inositol trisphosphate; MLCK, myosin light chain kinase; PLA₂, phospholipase A₂; PG, prostaglandins; EET, epoxyeicosatrienoic acid; HETE, hydroxyeicosatetraenoic acid; COX, cyclooxygenase; LT, leukotrienes; LO, lipoxygenase; TxA₂, thromboxane A₂; NO, nitric oxide.

thromboxane A₂, which promote vasoconstriction. Via lipoxygenase, ANG II also mediates the formation of leukotrienes, implicated in vasoconstriction, hypertension, and inflammatory diseases. Arachidonic acid metabolites hydroxyeicosatetraenoic acids (HETEs) are pro-hypertensive, and lead to ANG II-mediated smooth muscle vasoconstriction by facilitating Ca²⁺ entry into the cell (164). These are counter-regulated by cytochrome P450-mediated epoxyeicosatrienoic acid (EETs) and dihydroxyeicosatetraenoic acids (DiHETEs), which are anti-hypertensive. EET- and DiHETE-mediated vascular relaxation appears to occur via inhibition of calcium-activated potassium channels (24).

Besides VSMC contraction, G protein-mediated pathways also activate various downstream proteins that further enhance growth and migration related signaling. The duration and intensity of signaling by the G protein subunits of AT₁R is mediated by members of a class of regulators of G protein signaling (RGS); in particular, RGS2 is a key player in inhibiting the G_{αq} subunit and its subsequent actions. Grant and colleagues (57) showed that RGS2 mRNA is significantly upregulated within 24 hours of ANG II stimulation and this increase is partially PKC dependent. In RGS2-deficient mice, prolonged vasoconstriction in response to ANG II has been demonstrated. In addition, candesartan, an AT₁R antagonist, decreases blood pressure in these mice (70). Recently, it has been shown that the cardiovascular system differentially expresses RGS isoforms. Aorta contains RGS1–5, vena cava expresses RGS5, atria contain a high level of RGS1 and RGS2, while the left ventricle contains the highest level of RGS4 (3, 28). Of interest, RGS1–4 all attenuate ANG II/AT₁R signaling (28), and studying their role in vascular pathology warrants further research since they may be potential targets for therapeutic intervention.

NAD(P)H and ROS Signaling

Oxidative stress has been implicated in regulation of tyrosine kinases and phosphatases, expression of inflammatory genes, endothelial function, VSMC growth, and extracellular matrix formation (63, 153, 191, 219, 221). ANG II is a potent mediator of oxidative stress and oxidant signaling (186, 191, 201, 217). ANG II activates membrane NAD(P)H oxidases in VSMCs to produce ROS such as superoxide and hydrogen peroxide (H₂O₂), which are involved in the pleiotropic effects of ANG II (63, 153, 204, 221). The mechanism by which ANG II activates NAD(P)H oxidases remains under intense investigation. In aortic smooth muscle cells, the NAD(P)H oxidase subunits Nox1 and Nox4 are mainly responsible for ROS generation (103). ANG II-mediated activation of NAD(P)H oxidases involves the upstream mediators Src/EGFR/PI3K/Rac-1 (discussed below) and PLD/PKC/p47phox phosphorylation (174, 195).

Previously considered to be only toxic byproducts of metabolism, ROS are now known to be potent intercellular and intracellular second messengers that mediate signaling in pathways causing hypertension and vessel inflammation (63, 141). ROS such as H₂O₂ can reversibly modify cysteine residues and regulate activity of tyrosine phosphatases and peroxiredoxins (163). Superoxide can also modify heme groups and iron-sulfur centers on proteins, interfering with their function (8, 71). Many signaling molecules are now known to be ROS

sensitive, and many ANG II-mediated effects are dependent on ROS. For instance, ANG II-induced activation of p38MAPK depends on H₂O₂; in VSMCs that overexpress catalase (an enzyme that catabolizes H₂O₂), p38MAPK activation is inhibited. Similarly, activation of Akt/PKB, Src, EGFR, and many others is also ROS sensitive. Transcription factors, such as NF-κB, AP-1, and Nrf2, which are implicated in the pathogenesis of atherosclerosis, are also activated by ROS (26, 147, 172, 215). One of the most well established consequences of superoxide generated by ANG II is inactivation of nitric oxide (NO) in endothelial cells and VSMCs (64, 156). It has been shown that ROS also cause vessel inflammation by inducing release of cytokines and leukocyte adhesion molecules that increase recruitment of monocytes to the area of endothelial damage (121). Thus, interactions between ANG II signaling and ROS lead to changes in structural and functional characteristics of the vasculature and are critical in vascular pathology.

Mitogen-Activated Protein Kinases

Cellular protein synthesis and metabolism, transport, volume regulation, gene expression, and growth all depend on MAPKs. ANG II has been shown to activate signaling cascades that activate MAPKs, including extracellular signal-regulated kinase (ERK1/2), JNK, and p38MAPK, which are implicated in VSMC differentiation, proliferation, migration, and fibrosis (see Fig. 2) (182, 188).

The ERK pathway is the best characterized of the MAPK pathways. Binding of ANG II to AT₁R activates ERK1/2 within 5 minutes, and in VSMCs ERK 1/2 activity is blocked by inhibition of PLC, suggesting its dependency on calcium (42). Src and calcium-dependent kinase Pyk2 phosphorylate EGFR on tyrosine, leading to formation of the Shc/Grb2 complex and ERK activation. This scaffold permits activation of Raf, which in turn phosphorylates the MAPK/ERK kinase (MEK). Raf associates with the small G protein Ras, leading to MEK activation, and subsequent phosphorylation of ERK 1/2 on threonine/tyrosine residues (182); recently, PKC-ζ has also been shown to associate with Ras and activate ERK 1/2 (108, 109). The phosphatase MAP kinase phosphatase-1 (MKP-1) serves as a negative feedback control, inactivating ERK 1/2 (20). Interestingly, stimulation of AT₂R activates phosphatases that also block ERK-mediated activity (30, 72).

Recent data implicates ERK (p42/44 kinase) in ANG II-mediated VSMC contraction. Touyz et al. (192) showed that in VSMCs from human peripheral arteries, tyrosine kinases and the ERK signaling cascade play a role in Ca²⁺ and pHi pathways, which ultimately cause cell contraction; specifically, MEK/ERK may increase Ca²⁺ availability within cells. Of importance, PD98059 (an inhibitor of MEK) and Tyrphostin A-23 (tyrosine kinase inhibitor) attenuate contraction caused by ANG II (192). ERK has also been implicated in anti-apoptotic and pro-mitogenic effects, and activation of ERK1/2 and Akt/PKB has been shown to inhibit apoptosis (4, 111, 137). Furthermore, ERK 1/2 has been implicated in ANG II-induced cellular growth and protein synthesis via regulation of PHAS-1 (inhibitor of eukaryotic initiation factor 4E). Recently, it has been shown that Pyk2 is an upstream player in ANG II-mediated regulation of PHAS-1 via ERK 1/2 (155).

ANG II-mediated MAPK activation is followed by an increase in *c-fos* (activated by ERK) and *c-jun* (activated by




Fig. 2. ANG II regulates vascular smooth muscle cell survival, growth, and hypertrophy. Via activation of PKC, ANG II activates NAD(P)H oxidase, a major source of cellular ROS. In turn, NAD(P)H-derived reactive oxygen species activate the EGFR in a c-Src-dependent manner. Once activated, the AT₁R transactivates many tyrosine and nontyrosine kinase receptors to carry out its pleiotropic effects. ANG II mediates cell survival via p38/MAPKAPK-2, and PDK 1/Akt. Cell growth and hypertrophy are mediated by ANG II-mediated MAP kinases, p38MAPK, ERK and JNK, and the JAK/STAT pathway, which all lead to changes in transcription of cellular proteins. ADAM, activation of a disintegrin and metalloproteinase; JAK, Janus kinase; EGFR, epidermal growth factor receptor; HB-EGF, heparin-binding epidermal growth factor; ASK, apoptosis signal-regulating kinase; Trx, thioredoxin; ROS, reactive oxygen species; HSP, heat-shock protein; JNK, c-Jun NH₂-terminal kinase; Cav-1, caveolin-1; PKC, protein kinase C; MKP-1, MAP kinase phosphatase-1; PI3K, phosphatidylinositol 3-kinase; PDK-1,3-phosphoinositide-dependent kinase-1.

JNK) gene expression, as well as increased AP-1 activity. AP-1 is a transcription factor complex (formed from dimerization of c-Jun and c-Fos) and ultimately influences cell differentiation, migration, and adhesion by binding to gene promoter sequences (191). ANG II-induced enhanced activation of vascular MAP kinases such as ERK1/2 has also been implicated in hypertension and in micro- and macrovascular target-organ damage (80, 81).

In addition to activating ERK1/2, ANG II also stimulates MAP kinases that are associated with environmental stress, such as apoptosis signal regulating kinase 1 (ASK1), which subsequently induces JNK and p38MAPK related signaling (74, 190). JNK (phosphorylated by MEK 4/7) and p38MAPK (phosphorylated by MEK 3/6) are amongst the family of stress-induced kinases that influence cell survival, apoptosis, and differentiation. JNK and p38MAPK have also become known as important mediators of ANG II-induced vascular inflammation (47, 98). Recently, it has been shown that ASK 1 is needed for ROS-induced JNK and p38MAPK activation (190), and inhibition of ASK 1 by thioredoxin leads to inhibition of apoptosis (114). Izumiya et al. (84) also discovered that in vivo, ASK 1 is vital in ANG II-induced cardiomyocyte hypertrophy and remodeling. In hypertensive rats, JNK pathways in vascular and renal tissues have also been implicated in vascular remodeling (94).


It has been discovered that unlike ERK and p38MAPK activation, ANG II-induced JNK activation is independent of EGFR transactivation (40). As shown by Nishida and colleagues (136), ANG II-stimulated activation of JNK and p38MAPK depends on G $\alpha_{12/13}$ -mediated activation of Rho/Rho kinase, with resultant activation of the small G protein Rac and ROS production. Activation of the JNK pathway by ANG II can also occur via G α -mediated activation of PKC- δ , and subsequent stimulation of Pyk-2 and PDZ-RhoGEF-mediated Rho activation (142). Pathways downstream of Rho have been implicated in migration (171). In fact, the Rac effector p21-activated kinase (α -PAK), which is rapidly activated upon ANG II stimulation, has been identified as being upstream of

JNK in VSMCs (169). ANG II-mediated activation of p38MAPK occurs via NAD(P)H oxidase-derived ROS (196); p38MAPK leads to stimulation of MAPKAPK-2, which serves to phosphorylate heat shock protein HSP-27, a stress-induced protein needed to chaperone and stabilize intracellular proteins (181, 188). In addition, p38MAPK also plays a role in ANG II-induced activation of Akt, a kinase with multiple downstream effects, including glucose metabolism and protein synthesis. These varied effects of ANG II-mediated MAPKs may provide more links between oxidant stress, hypertension, hyperlipidemia, and diabetes in the development of inflammation and atherosclerosis.

Nonreceptor Tyrosine Kinases

Src pathway. Even though AT₁R lacks intrinsic kinase activity, nonreceptor tyrosine kinases associate with AT₁R and initiate signaling events that lead to phosphorylation and activation of several intracellular proteins. In recent years, Src has surfaced as a key player in ANG II-mediated cellular effects (Figs. 2 and 3). c-Src is a tyrosine kinase that has been shown to be activated by G $\beta\gamma$ in a ROS-dependent manner, and it is involved in activation of a variety of downstream pathways, including Ras, FAK, JAK/STAT, and PLC- γ (leading to sustained calcium release). Src kinase and its substrates such as FAK and Pyk2 (also known as cell adhesion kinase- β) associate with paxillin, talin, and p130Cas to form a complex involved in JNK-mediated activation of AP-1 (see Fig. 3). Pyk2 activation by ANG II is dependent on Ca²⁺ and PKC in VSMCs (161), and further activates c-Src and 3-phosphoinositide-dependent kinase (PDK)-1, leading to cell growth and assembly of focal adhesion complexes (189). Interestingly, Ishida et al. (81) found that in VSMCs stimulated by ANG II, c-Src is involved in focal adhesion complex formation and actin bundling; furthermore, VSMCs lacking c-Src had less tyrosine phosphorylation of p130Cas, paxillin, and tensin. Important in focal adhesion signaling through the extracellular matrix, FAK and Pyk2 are rapidly phosphorylated by ANG II,

Fig. 3. ANG II promotes cell adhesion and extracellular matrix formation. A cell's ability to survive with various environmental stressors is also regulated by kinases such as JNK, which has been found to be downstream of α -PAK and Rac, second messengers activated by AT₁R signaling. ANG II-induced association of FAK, Pyk2, paxillin, talin, and p130Cas forms a complex that promotes cellular adhesion and extracellular matrix synthesis via JNK activation. Evidence shows that calcium plays a vital role in mediating these ANG II-induced processes. JNK activation by ANG II can also occur via Gq and G $\alpha_{12/13}$, with RhoA/RhoA kinase activation. RGS, regulators of G protein signaling; ROS, reactive oxygen species; JNK, c-Jun NH₂-terminal kinase; FAK, focal adhesion kinase; GEF, guanine nucleotide exchange factor; PDK1, 3-phosphoinositide-dependent kinase 1; PKC, protein kinase C; PLD, phospholipase D; α -PAK, p21 activated kinase; AP-1, activator protein-1; ROCK, RhoA kinase.



further illuminating the critical cytokine-like properties of ANG II in mediating cellular growth (17).

JAK/STAT pathway. The activated AT₁R also induces the JAK/STAT mitogenic pathway. Upon activation by JAK, STAT proteins dimerize via sulfhydryl-phosphotyrosine interactions, and translocate to the nucleus, where they mediate gene transcription of early growth response genes, such as *c-fos* and *c-myc* (17, 81, 117). It has been discovered that ANG II stimulates the association of JAK2 with AT₁R via tyrosine phosphatase SHP-2; the COOH terminus of AT₁R serves as a docking site for JAK2, and stimulates JAK2 phosphorylation at Tyr^{1007/1008} (48, 119). Frank and colleagues (48) showed that in VSMCs, PLC and its downstream second messengers, IP₃/Ca²⁺ and DAG/PKC, are necessary for G protein-mediated, ANG II-induced JAK2 activation. Furthermore, this activation is dependent on PKC- δ and Pyk2. ANG II-activated JAK/STAT signaling is blocked by SHP-1, a phosphatase that causes JAK2 dephosphorylation (120). Via JAK/STAT signaling, ANG II exhibits its multifaceted role in mediating VSMC growth, migration, and remodeling.

FAK and Pyk2 pathway. In response to various pathologic stimuli, cells reorganize their cytoskeletal structure to promote survival, migration, adhesion, and apoptosis. ANG II signaling through the cytoskeleton integrates many growth and redox signaling pathways. ANG II regulates formation of focal adhesion complexes, specialized areas of cells that promote cell adhesion (144). Associated with focal adhesion complexes in the actin cytoskeleton, the 125-kDa protein, FAK, is highly expressed in the arterial media and in cultured VSMCs and mediates cell adhesion (150) (Fig. 3). ANG II rapidly induces tyrosine phosphorylation of FAK to allow for cell adhesion to the extracellular matrix, and to enable activation of cytoskeletal proteins, including p130Cas, Pyk2 (41), paxillin (104), and talin (160), all of which interact to regulate cell shape and movement. p130Cas is an adaptor molecule whose proline-rich sequences and SH3 domain allow for an interaction with Pyk2 in presence of ANG II (154). It has also been shown that the interaction between p130Cas, Pyk2, and PI3K activates ribo-

somal p70^{S6} kinase, implicated in ANG II-mediated protein synthesis.

Receptor Tyrosine Kinases

PDGF receptor pathway. Migration and proliferation of VSMCs is critical in the pathogenesis of vascular disease, and platelet-derived growth factor (PDGF) is a potent stimulus for VSMC migration and proliferation (18, 100, 106, 223). Similar to other cell membrane tyrosine kinase receptors (EGFRs and insulin receptors), the PDGF receptor has an intrinsic tyrosine kinase activity. Both PDGF and ANG II activate several common pathways (such as MAPK and PLC) that are implicated in VSMC hypertrophy. ANG II has been shown to transduce growth-related signaling, independent of PDGF, via the PDGF receptor. It has been shown that ANG II stimulates PDGF- β -receptor phosphorylation via Shc, independent of calcium (68). Linesman and colleagues (112) showed that stimulation of rat aortic smooth muscle cells by ANG II induced the formation of a Shc and Grb2 complex with the PDGF receptor independent of PDGF, a response blocked by losartan. Other evidence shows that ANG II induces tyrosine phosphorylation of PDGF- β -receptor and increases ERK activity of rat VSMCs in vitro (112). In stroke-prone spontaneously hypertensive rats, treatment with ACE-I reduced aortic PDGF- β -receptor phosphorylation and ERK activity (96), implicating PDGF as downstream of RAS in hypertensive vascular remodeling.

Epidermal growth factor receptor pathway (EGFR). Trans-activation of EGFR is a major mechanism by which ANG II influences growth-related signaling pathways. ANG II-mediated EGFR activation occurs in the cholesterol-rich domains of caveolae in a Src-dependent and redox-sensitive manner (58, 203). Studies show that this activation is also dependent on intact microtubules and occurs via calcium-dependent and -independent pathways (43, 203). These pathways lead to activation of a disintegrin and metalloproteinase (ADAMs), causing release of heparin-binding EGF (HB-EGF) (5, 19). Recently, in COS-7 cells, ANG II-activated ADAM-17 has

been identified as the metalloproteinase that promotes HB-EGF shedding (123, 140). HB-EGF induces conformational changes in EGFRs, allowing them to dimerize and autophosphorylate on tyrosine (151). Once activated, EGFRs serve as a docking site for Grb2/Shc/Sos complexes, inducing two major transduction pathways: the PI3K/PDK1/Akt cascade, which leads to cellular metabolism, growth, survival, and remodeling, and the Ras/Raf/ERK pathway which leads to cell growth, hypertrophy, and inflammation. Kagiya et al. (87) reported that EGFR activation is required for ANG II-mediated hypertension and left ventricular hypertrophy, both of which are attenuated when rats are treated with an intravenous infusion of antisense oligodeoxynucleotide to EGFR. These studies and many others point to EGFR as an important factor in growth and hypertrophy caused by ANG II.

Insulin Receptor Signaling Pathway. In addition to direct activation of signaling pathways, ANG II influences signal transduction mechanisms induced by other agonists as well. A prime example of this is insulin signaling. In vivo studies in rats show that infusion of ANG II induces insulin resistance (139, 148); patients with an imbalance in RAS homeostasis exhibit decreased insulin sensitivity (99, 138). Further proof of this observation is that pharmacological blockade of the RAS with ACE-I and ARBs improves insulin resistance and diabetic complications (69, 77).

The insulin receptor's ability to autophosphorylate and phosphorylate other substances results in activation of pathways that lead to insulin's metabolic, transcriptional, and mitogenic effects (146). Once activated, the insulin receptor induces tyrosine phosphorylation of insulin receptor substrate (IRS-1), which enables its interaction with p85 (regulatory subunit of PI3K), activating the PI3K pathway, its downstream effectors PDK1 and Akt, and ultimately glucose transport. Serine phosphorylation inactivates IRS-1 both by uncoupling it from downstream effectors and by targeting it for degradation in the proteasomal pathway (129, 208). Even though as many as 35 potential serine/threonine phosphorylation sites have been identified on IRS-1, murine Ser³⁰⁷ (human Ser³¹²) has become apparent as an important site in its proteasome-mediated degradation (59).

Folli et al. (46) showed that in rat aortic smooth muscle cells, ANG II impairs insulin-mediated IRS-1 tyrosine phosphorylation and coupling of the insulin receptor to PI3K. ANG II has also been shown to increase serine phosphorylation of the insulin receptor β -subunit, and has a direct effect on PI3K activity by increasing serine phosphorylation of p85 (46). In addition, ANG II inhibits insulin-stimulated IRS-1 association with p85 in a dose-dependent manner. Another mechanism by which ANG II interferes with insulin signaling emerges from the fact that ANG II stimulates tyrosine phosphorylation of PDK1 on Tyr⁹ (protein interacting domain) in a Src-dependent, ROS-sensitive manner (188). In the presence of mutant PDK1, ANG II-induced serine phosphorylation of IRS-1 is reduced, inhibiting its degradation, and suggesting that PDK1 is involved in ANG II-induced insulin resistance (187). Other kinases such as PKC- α have also been shown to interfere with insulin signaling via ANG II (126). Furthermore, Andreozzi et al. (6) recently demonstrated that in human umbilical vein endothelial cells, ANG II increases phosphorylation of IRS-1 Ser⁶¹⁶ (via ERK) and IRS-1 Ser³¹² (via JNK), causing impaired insulin signaling. Hypertension and diabetes often present

together, indicating that interaction between ANG II and insulin signaling plays an important role in cardiovascular pathology. Interruption of IRS-1 signaling by ANG II at multiple levels may explain the severity of vascular disease seen in diabetic patients.

PHYSIOLOGICAL EFFECTS OF ANG II

The physiological importance of ANG II in the cardiovascular system cannot be overstated. Within seconds to minutes of binding to AT₁Rs, it activates signaling pathways leading to VSMC contraction, maintaining vascular tone. ANG II is extremely important in modulating minute to minute changes that occur in our spatial adaptation. For example, when we stand up from a supine position, the endocrine function of ANG II allows for increased myocardial activity (via enhanced inotropy and chronotropy) that appears to occur via augmentation of inward Ca²⁺ current through L-type channels (10). In addition to stimulating the synthesis and release of aldosterone and increasing renal Na⁺ absorption, ANG II's actions on the central nervous system are critical in maintaining sympathetic outflow to the vasculature and in autoregulating cerebral blood flow. ANG II serves as a focal point in integration of all of these complex processes to help maintain blood pressure and perfuse vital organs. ANG II's cytokine-like effects usually occur with longer exposure, and promote cell growth and migration, extracellular matrix deposition, and vascular and electrical remodeling. When the balance of the RAS is perturbed (due to genetic, environmental, and lifestyle factors), pathological effects of ANG II develop.


CARDIOVASCULAR PATHOLOGY

ANG II affects virtually all vascular cells (endothelial cells, smooth muscle cells, fibroblasts, monocytes/macrophages, and even cardiac myocytes), and thus, is critical in disease development (Fig. 4). Changes in the phenotype and morphology of these cells, variable gene expression, and enhanced responsiveness to stimuli lead to vascular pathology. In atherosclerotic plaques, the local RAS system is active, with high levels of ACE, ANG II, and AT₁R (167). Antagonism of actions of ANG II may slow atherosclerotic disease progression and stabilize vulnerable plaques, partially explaining the benefits seen with ACE-I and ARB therapy.

ANG II and Endothelial Dysfunction

Even though the principal targets of ANG II are VSMCs, it has multiple effects on endothelial cells (ECs), such as producing ROS, activating apoptotic signaling pathways, and promoting thrombosis. In endothelial cells, ANG II regulates the production of NO, formed by nitric oxide synthase (NOS). Exposure to ANG II increases eNOS mRNA and NO production in human endothelial cells (166). In people with enhanced RAS activity, ROS-mediated endothelial dysfunction combined with vascular growth and inflammation has been implicated in atheroma formation. The increase in oxidative stress caused by ANG II leads to impaired endothelial relaxation and endothelial dysfunction (153). The intracellular ROS have been shown to activate transcription of nuclear factor κ B (NF- κ B) and stimulate degradation of its cytoplasmic inhibitor, I κ B (152). NF- κ B gene expression results in increased levels of VCAM-1, an important factor in endothelial cell adhesion.

Fig. 4. ANG II's role in cardiovascular pathology. The octapeptide ANG II exerts its myriad effects in modulating cardiovascular physiology and pathology by inducing signaling pathways in vascular smooth muscle cells, endothelial cells, and cardiac fibroblasts, and by affecting their interaction with the extracellular matrix. Convergence of these cascades of events, in addition to abnormalities in the coagulation system, ultimately lead to atherosclerosis and thrombosis with the final development of clinically observable signs and symptoms of cardiovascular disease.



This observation is concordant with the report from Arenas et al. (7), who showed that ANG II modulates the secretion of inflammatory cytokines TNF- α and matrix metalloproteinase (MMP)-2 from ECs. TNF- α is also an important contributor to vascular inflammation, and its levels are elevated in vascular disorders. Many of the effects of TNF- α are similar to effects of ANG II; indeed, ANG II has been shown to stimulate the production of TNF- α through a PKC-dependent pathway in macrophages (89).

In the vessel wall, homeostatic mechanisms balance thrombosis with fibrinolysis. Plasminogen-activator inhibitor type 1 (PAI-1) inhibits tissue plasminogen activator (t-PA) and urokinase, tipping the balance in favor of thrombosis. In VSMCs and ECs, exposure to ANG II leads to increased levels of PAI-1 mRNA (45). ANG II-mediated inhibition of fibrinolysis and its induction of cell adhesion molecules such as VCAM-1 and ICAM-1 (via NF- κ B activation) provide for further mechanisms by which ANG II initiates and causes progression of atherosclerosis. In endothelial cells, ANG II has been shown to induce the LDL receptor (107), which is critical in atherosclerotic lesion formation. Thus, ANG II plays a key role in modulating endothelial function, and its enhanced presence contributes to endothelial dysfunction and inflammation.

ANG II and Vascular Inflammation

The role of ANG II in atherosclerosis has been well established. In apolipoprotein E-deficient mice, infusion of ANG II causes accelerated atherosclerosis and aneurysm formation (1, 211). In monocytes, macrophages, VSMCs, and endothelial cells, ANG II activates NF- κ B, which induces the production of cell adhesion molecules such as VCAM-1, ICAM-1, and E-selectin, and chemokines such as monocyte chemoattractant protein (MCP-1), IL-6, and IL-8 (157, 158, 167). In VSMCs, the induction of MCP-1 and IL-6 by ANG II is dependent on the activation of NAD(P)H oxidase (27, 97, 121).

Cytokines have been shown to play a major part in development and progression of atherosclerotic lesion formation. For example, human atherosclerotic plaques express elevated

levels of the inflammatory cytokine interleukin-18 (IL-18) compared with normal arterial tissue (54). Recently, in a series of experiments, Sahar et al. (162) demonstrated that IL-18 activates Src, PKC, and MAPK. In ANG II-stimulated VSMCs, the effects of IL-18 were enhanced via activation of NF- κ B; ANG II also induced mRNA expression of IL-18 α receptors via STAT 3. The cross-talk with IL-18 signaling pathways may prove to be one of the mechanisms by which ANG II mediates its local proatherogenic effects in VSMCs.

ANG II and Vascular Hypertrophy and Remodeling

Over the past decade, *in vitro* and *in vivo* experiments have shown that ANG II is an important growth factor, causing cell proliferation, VSMC hypertrophy, cell differentiation, and apoptosis (38). Depending on the cell type and cytokine milieu, ANG II appears to have different growth effects (proliferation vs. hypertrophy). These differential growth effects are in part regulated by p27^{kip1}, a cyclin-dependent kinase (CDK) inhibitor; CDKs are suppressed in presence of high levels of p27^{kip1}, preventing cells from progressing in the cell cycle. Braun-Dullaeus et al. (22) showed that in ANG II-treated VSMCs, CDK2 activity was suppressed (secondary to failure of p27^{kip1} repression), leading to G1-phase arrest and cell hypertrophy.

Another mechanism implicating ANG II in cell growth comes from the observation that elevation in blood pressure affects cell growth. In rats, ANG II infusion for 2 wk. leads to hypertension and VSMC hypertrophy (115). Shear stress from elevated blood pressure has been shown to upregulate ANG II receptors (157), linking hypertension to vascular remodeling. ANG II also stimulates the production of MMPs, which are necessary for vascular remodeling (39).

Many studies support the observation that ANG II also has direct effects on myocardial cells, including hypertrophy (36, 113, 149). These effects are known to be mediated by AT₁Rs; *in vivo* experiments in rats show that AT₁R antagonists prevent ANG II-induced cardiac hypertrophy (95). The AT₁R also has been shown to play a role in neointima formation via prolifer-

eration of VSMCs after balloon injury (93). Kim et al. (95) showed that in rat arteries, blockade of ANG II inhibits activation of ERK/MAPKs, which are implicated in apoptosis and cell proliferation.

ANG II and Extracellular Matrix

In the pathogenesis of atherosclerosis and restenosis, cellular deposition of extracellular matrix (ECM) is an important component in VSMC migration and adhesion. Accumulation of ECM and reduced ECM turnover play a role in the development of vascular restenosis, hypertrophy, and heart failure after an ischemic insult to the myocardium. ANG II has been implicated in synthesis of the extracellular matrix protein collagen via both AT₁Rs and AT₂Rs (90, 124). ANG II-induced EGFR- and MAPK-dependent pathways may participate in matrix formation and regulation (122, 193). Indeed, ACE inhibition has been shown to limit cardiac remodeling. Fibroblast-derived ANG II exerts its local paracrine effects by stimulating the production of collagen (86). In atherosclerotic lesions, abnormal accumulation of proteoglycans has been noted (44, 79). In hypertensive rats, AT₁R antagonists cause proteoglycan changes that control cell adhesion, migration, and differentiation (79, 165). Shimizu-Hirota et al. (176) showed that the ANG II-induced increase in proteoglycan synthesis was attenuated by the EGFR inhibitor AG1478 and by the MEK inhibitor PD98059. Besides regulating structural components such as collagen, ANG II has also been implicated in adhesive remodeling. Earlier, Moriguchi et al. (125) reported that ANG II-mediated EGFR transactivation regulates fibronectin and TGF- β synthesis. Furthermore, production of matrix metalloproteinases (like MMP-2) and breakdown of collagen IV is also modulated by ANG II (110). Thus, ANG II acts on several different components of ECM formation and deposition to influence matrix turnover, and many of the mechanisms and pathways that integrate ECM formation and deposition with ANG II signaling are still being discovered.

ANG II AND VASCULAR DISEASE

Pathologic ANG II-induced signaling in vascular, endothelial, and cardiac cells promotes ROS production, inflammation, platelet activation, altered vasoreactivity, growth, migration, and fibrosis, all of which combine to ultimately cause diseases such as hypertension, atherosclerosis, restenosis, heart failure, chronic kidney disease, insulin resistance, and tumor progression. Improved clinical outcomes after treatment with ACE-Is and ARBs confirms the importance of ANG II in the pathogenesis of these diseases (51, 77, 220). ANG II may also provide a link between atherosclerotic risk factors such as hypercholesterolemia and hypertension, since high cholesterol levels have recently been shown to increase angiotensinogen and angiotensin (34). In apolipoprotein E-deficient mice, inhibition of AT₁Rs by losartan (an ARB) prevents lipid peroxidation, decreasing atherosclerotic lesion formation (91). Conversely, ANG II infusion increases aortic atherosclerosis and aneurysm formation, independent of blood pressure (33). Male apoE/AT_{1A}R double knockout mice also have reduced atherosclerosis, indicating that alterations in AT₁R expression affect vascular pathology (210). Furthermore, Yang et al. (218) have shown that in hypercholesterolemic rabbits, AT₁R expression is increased, which results in altered ANG II-induced vasore-

activity and may lead to pathology. Consistent with this is the finding that after neointimal injury, ANG II receptor expression is increased (209).

Recently, other beneficial effects of ACE-Is and ARBs have been discovered. Interestingly, peroxisome proliferator-activated receptor (PPAR) agonists reduce ANG II-induced oxidative stress, inflammation, and hypertension (35). Telmisartan (an ARB) modulates PPAR- γ , a therapeutic target of diabetic drugs (15). Another PPAR- γ agonist, rosiglitazone, lowers blood pressure and improves vascular function in transgenic hypertensive mice that express human renin and angiotensinogen genes (159). These recent developments provide insight into the mechanisms by which the RAS and AT₁Rs interact with other systems to influence cardiovascular pathology.

CONCLUSIONS AND FUTURE DIRECTIONS

The pathogenesis of chronic vascular diseases is dependent on cross-talk of various cell signaling systems. In VSMCs and ECs, interactions between lipoproteins, the RAS, and insulin is key to understanding the development and progression of vascular diseases, including hypertension, diabetes, myocardial infarction, stroke, transplant vasculopathy, and in-stent restenosis. In recent years, ANG II has been shown to generate oxidative stress in vessel wall, and has proved to be a major stimulator of inflammation, thrombosis, and fibrosis. The specifics of the signal transduction pathways mediated by ANG II remain under intense investigation, and the many downstream effectors of AT₁Rs pose exciting therapeutic venues. However, most of the experiments have involved in vitro studies, and discovering the mechanisms of these pathways in vivo has posed a challenge. Novel pharmacological approaches such as virus-mediated gene delivery to block various components of the RAS and study the subsequent effects are exciting. Transgenic and knockin/knockout rodents have revolutionized our efforts to discover the mechanisms of ANG II signaling, and other animal models will provide even a greater insight into the workings of the RAS. Much work yet remains to be accomplished to advance our knowledge of the RAS in the pathogenesis of cardiovascular disease and to develop therapeutic strategies to ultimately affect morbidity and mortality.

GRANTS

This work was supported by National Heart, Lung and Blood Institute Grants HL-38206, HL-58000, and HL-70115.

REFERENCES

1. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT₂ receptor is an AT₁ receptor antagonist. *J Biol Chem* 276: 39721–39726, 2001.
2. AbdAlla S, Lother H, Quitterer U. AT₁-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. *Nature* 407: 94–98, 2000.
3. Adams LD, Geary RL, McManus B, Schwartz SM. A comparison of aorta and vena cava medial message expression by cDNA array analysis identifies a set of 68 consistently differentially expressed genes, all in aortic media. *Circ Res* 87: 623–631, 2000.
4. Allen RT, Krueger KD, Dhume A, Agrawal DK. Sustained Akt/PKB activation and transient attenuation of c-jun N-terminal kinase in the inhibition of apoptosis by IGF-1 in vascular smooth muscle cells. *Apoptosis* 10: 525–535, 2005.
5. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH, Schlessinger J. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-

- activated protein (MAP) kinase signaling cascade. *J Biol Chem* 276: 20130–20135, 2001.
6. **Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G.** Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. *Circ Res* 94: 1211–1218, 2004.
 7. **Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST.** Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF- α . *Am J Physiol Cell Physiol* 286: C779–C784, 2004.
 8. **Arredondo M, Nunez MT.** Iron and copper metabolism. *Mol Aspects Med* 26: 313–327, 2005.
 9. **Baines RJ, Brown C, Ng LL, Boarder MR.** Angiotensin II-stimulated phospholipase C responses of two vascular smooth muscle-derived cell lines. Role of cyclic GMP. *Hypertension* 28: 772–778, 1996.
 10. **Baker KM, Booz GW, Dostal DE.** Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. *Annu Rev Physiol* 54: 227–241, 1992.
 11. **Barki-Harrington L, Luttrell LM, Rockman HA.** Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. *Circulation* 108: 1611–1618, 2003.
 12. **Barrett JD, Zhang Z, Zhu JH, Lee DB, Ward HJ, Jamgotchian N, Hu MS, Fredal A, Giordani M, Eggena P.** Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. *J Hypertens* 16: 1749–1757, 1998.
 13. **Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C.** Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. *Biochem J* 325: 449–454, 1997.
 14. **Benetos A, Topouchian J, Ricard S, Gautier S, Bonnardeaux A, Asmar R, Poirier O, Soubrier F, Safar M, Cambien F.** Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients. *Hypertension* 26: 44–47, 1995.
 15. **Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW.** Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity. *Hypertension* 43: 993–1002, 2004.
 16. **Berge KE, Bakken A, Bohn M, Erikssen J, Berg K.** A DNA polymorphism at the angiotensin II type 1 receptor (AT1R) locus and myocardial infarction. *Clin Genet* 52: 71–76, 1997.
 17. **Berk BC, Corson MA.** Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. *Circ Res* 80: 607–616, 1997.
 18. **Bilato C, Pauly RR, Melillo G, Monticone R, Gorelick-Feldman D, Gluzband YA, Sollott SJ, Ziman B, Lakatta EG, Crow MT.** Intracellular signaling pathways required for rat vascular smooth muscle cell migration. Interactions between basic fibroblast growth factor and platelet-derived growth factor. *J Clin Invest* 96: 1905–1915, 1995.
 19. **Blobel CP.** ADAMs: key components in EGFR signalling and development. *Nat Rev Mol Cell Biol* 6: 32–43, 2005.
 20. **Bokemeyer D, Lindemann M, Kramer HJ.** Regulation of mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle cells. *Hypertension* 32: 661–667, 1998.
 21. **Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F.** Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. *Hypertension* 24: 63–69, 1994.
 22. **Braun-Dullaues RC, Mann MJ, Ziegler A, von der Leyen HE, Dzau VJ.** A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. *J Clin Invest* 104: 815–823, 1999.
 23. **Bumpus FM, Catt KJ, Chiu AT, DeGasparo M, Goodfriend T, Husain A, Peach MJ, Taylor DG Jr, Timmermans PB.** Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. *Hypertension* 17: 720–721, 1991.
 24. **Campbell WB, Gebremedhin D, Pratt PF, Harder DR.** Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. *Circ Res* 78: 415–423, 1996.
 25. **Chen X, Li W, Yoshida H, Tsuchida S, Nishimura H, Takemoto F, Okubo S, Fogo A, Matsusaka T, Ichikawa I.** Targeting deletion of angiotensin type 1B receptor gene in the mouse. *Am J Physiol Renal Physiol* 272: F299–F304, 1997.
 26. **Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, Kunsch C.** Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. *Am J Physiol Heart Circ Physiol* 290: H1862–H1870, 2006.
 27. **Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM.** Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. *Circ Res* 83: 952–959, 1998.
 28. **Cho H, Harrison K, Schwartz O, Kehrl JH.** The aorta and heart differentially express RGS (regulators of G-protein signalling) proteins that selectively regulate sphingosine 1-phosphate, angiotensin II and endothelin-1 signalling. *Biochem J* 371: 973–980, 2003.
 29. **Crackower MA, Sarao R, Oudit GY, Yagil C, Koziarzdzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM.** Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 417: 822–828, 2002.
 30. **Cui T, Nakagami H, Iwai M, Takeda Y, Shiuchi T, Daviet L, Nahmias C, Horiuchi M.** Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. *Cardiovasc Res* 49: 863–871, 2001.
 31. **D'Amore A, Black MJ, Thomas WG.** The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. *Hypertension* 46: 1347–1354, 2005.
 32. **Danilczyk U, Penninger JM.** Angiotensin-converting enzyme II in the heart and the kidney. *Circ Res* 98: 463–471, 2006.
 33. **Daugherty A, Manning MW, Cassis LA.** Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin Invest* 105: 1605–1612, 2000.
 34. **Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA.** Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. *Circulation* 110: 3849–3857, 2004.
 35. **Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL.** PPAR α activator effects on Ang II-induced vascular oxidative stress and inflammation. *Hypertension* 40: 866–871, 2002.
 36. **Dorn GW 2nd, Force T.** Protein kinase cascades in the regulation of cardiac hypertrophy. *J Clin Invest* 115: 527–537, 2005.
 37. **Du G, Huang P, Liang BT, Frohman MA.** Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis. *Mol Biol Cell* 15: 1024–1030, 2004.
 38. **Dzau VJ.** Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. *Hypertension* 37: 1047–1052, 2001.
 39. **Dzau VJ, Gibbons GH, Pratt RE.** Molecular mechanisms of vascular renin-angiotensin system in myocardial hyperplasia. *Hypertension* 18: 1100–105, 1991.
 40. **Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T.** Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloproteinase-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. *J Biol Chem* 276: 7957–7962, 2001.
 41. **Eguchi S, Iwasaki H, Inagami T, Numaguchi K, Yamakawa T, Motley ED, Owada KM, Marumo F, Hirata Y.** Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells. *Hypertension* 33: 201–206, 1999.
 42. **Eguchi S, Matsumoto T, Motley ED, Utsunomiya H, Inagami T.** Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. Possible requirement of Gq-mediated p21ras activation coupled to a Ca²⁺/calmodulin-sensitive tyrosine kinase. *J Biol Chem* 271: 14169–14175, 1996.
 43. **Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T.** Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. *J Biol Chem* 273: 8890–8896, 1998.
 44. **Evanko SP, Raines EW, Ross R, Gold LI, Wight TN.** Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor- β . *Am J Pathol* 152: 533–546, 1998.

45. **Feener EP, Northrup JM, Aiello LP, King GL.** Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. *J Clin Invest* 95: 1353–1362, 1995.
46. **Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP.** Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. *J Clin Invest* 100: 2158–2169, 1997.
47. **Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM.** Stress-activated protein kinases in cardiovascular disease. *Circ Res* 78: 947–953, 1996.
48. **Frank GD, Saito S, Motley ED, Sasaki T, Ohba M, Kuroki T, Inagami T, Eguchi S.** Requirement of Ca^{2+} and PKC δ for Janus kinase 2 activation by angiotensin II: involvement of PYK2. *Mol Endocrinol* 16: 367–377, 2002.
49. **Fukuyama K, Ichiki T, Takeda K, Tokunou T, Iino N, Masuda S, Ishibashi M, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A.** Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. *Hypertension* 41: 598–603, 2003.
50. **Gaborik Z, Hunyady L.** Intracellular trafficking of hormone receptors. *Trends Endocrinol Metab* 15: 286–293, 2004.
51. **Garg R, Yusuf S.** Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *JAMA* 273: 1450–1456, 1995.
52. **Gasc JM, Shanmugam S, Sibony M, Corvol P.** Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. *Hypertension* 24: 531–537, 1994.
53. **Geisterfer AA, Peach MJ, Owens GK.** Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. *Circ Res* 62: 749–756, 1988.
54. **Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U.** Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. *J Exp Med* 195: 245–257, 2002.
55. **Giugliano D, Ceriello A, Paolisso G.** Oxidative stress and diabetic vascular complications. *Diabetes Care* 19: 257–267, 1996.
56. **Goldsmith SR.** Interactions between the sympathetic nervous system and the RAAS in heart failure. *Curr Heart Fail Rep* 1: 45–50, 2004.
57. **Grant SL, Lassegue B, Griendling KK, Ushio-Fukai M, Lyons PR, Alexander RW.** Specific regulation of RGS2 messenger RNA by angiotensin II in cultured vascular smooth muscle cells. *Mol Pharmacol* 57: 460–467, 2000.
58. **Gratton JP, Bernatchez P, Sessa WC.** Caveolae and caveolins in the cardiovascular system. *Circ Res* 94: 1408–1417, 2004.
59. **Greene MW, Sakaue H, Wang L, Alessi DR, Roth RA.** Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. *J Biol Chem* 278: 8199–8211, 2003.
60. **Griendling KK, Delafontaine P, Rittenhouse SE, Gimbrone MA Jr, Alexander RW.** Correlation of receptor sequestration with sustained diacylglycerol accumulation in angiotensin II-stimulated cultured vascular smooth muscle cells. *J Biol Chem* 262: 14555–14562, 1987.
61. **Griendling KK, Lassegue B, Alexander RW.** Angiotensin receptors and their therapeutic implications. *Annu Rev Pharmacol Toxicol* 36: 281–306, 1996.
62. **Griendling KK, Lassegue B, Murphy TJ, Alexander RW.** Angiotensin II receptor pharmacology. *Adv Pharmacol* 28: 269–306, 1994.
63. **Griendling KK, Sorescu D, Ushio-Fukai M.** NAD(P)H oxidase: role in cardiovascular biology and disease. *Circ Res* 86: 494–501, 2000.
64. **Gryglewski RJ, Palmer RM, Moncada S.** Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. *Nature* 320: 454–456, 1986.
65. **Gunther S, Gimbrone MA Jr, Alexander RW.** Regulation by angiotensin II of its receptors in resistance blood vessels. *Nature* 287: 230–232, 1980.
66. **Guo DF, Inagami T.** Epidermal growth factor-enhanced human angiotensin II type 1 receptor. *Hypertension* 23: 1032–1035, 1994.
67. **Hansen JL, Theilade J, Haunso S, Sheikh SP.** Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation. *J Biol Chem* 279: 24108–24115, 2004.
68. **Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC.** Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. *J Biol Chem* 275: 15926–15932, 2000.
69. **Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M.** Selective angiotensin II receptor antagonist reduces insulin resistance in obese Zucker rats. *Hypertension* 38: 884–890, 2001.
70. **Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP, Blumer KJ.** Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. *J Clin Invest* 111: 1259, 2003.
71. **Hidalgo E, Dimple B.** An iron-sulfur center essential for transcriptional activation by the redox-sensing SoxR protein. *EMBO J* 13: 138–146, 1994.
72. **Horiuchi M, Akishita M, Dzau VJ.** Molecular and cellular mechanism of angiotensin II-mediated apoptosis. *Endocr Res* 24: 307–314, 1998.
73. **Hunyady L, Catt KJ.** Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. *Mol Endocrinol* 20: 953–970, 2006.
74. **Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y.** Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science* 275: 90–94, 1997.
75. **Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A.** Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 21: 1896–1901, 2001.
76. **Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A.** Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. *Hypertension* 31: 342–348, 1998.
77. **Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M, Daimon M, Kato T.** Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. *Hypertension* 38: 1255–1259, 2001.
78. **Ikeda Y, Takeuchi K, Kato T, Taniyama Y, Sato K, Takahashi N, Sugawara A, Ito S.** Transcriptional suppression of rat angiotensin AT1a receptor gene expression by interferon-gamma in vascular smooth muscle cells. *Biochem Biophys Res Commun* 262: 494–498, 1999.
79. **Iozzo RV.** Matrix proteoglycans: from molecular design to cellular function. *Annu Rev Biochem* 67: 609–652, 1998.
80. **Ishida M, Ishida T, Thomas SM, Berk BC.** Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. *Circ Res* 82: 7–12, 1998.
81. **Ishida T, Ishida M, Suero J, Takahashi M, Berk BC.** Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src. *J Clin Invest* 103: 789–797, 1999.
82. **Ishizaka N, Alexander RW, Laursen JB, Kai H, Fukui T, Oppermann M, Lefkowitz RJ, Lyons PR, Griendling KK.** G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta. Regulation by angiotensin II and hypertension. *J Biol Chem* 272: 32482–32488, 1997.
83. **Ishizaka N, Griendling KK, Lassegue B, Alexander RW.** Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. *Hypertension* 32: 459–466, 1998.
84. **Izumiya Y, Kim S, Izumi Y, Yoshida K, Yoshiyama M, Matsuzawa A, Ichijo H, Iwao H.** Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. *Circ Res* 93: 874–883, 2003.
85. **Jin L, Ying Z, Hilgers RH, Yin J, Zhao X, Imig JD, Webb RC.** Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. *J Pharmacol Exp Ther* 318: 288–295, 2006.
86. **Ju H, Dixon IM.** Extracellular matrix and cardiovascular diseases. *Can J Cardiol* 12: 1259–1267, 1996.
87. **Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI.** Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. *Circulation* 106: 909–912, 2002.
88. **Kai H, Griendling KK, Lassegue B, Ollerenshaw JD, Runge MS, Alexander RW.** Agonist-induced phosphorylation of the vascular type 1 angiotensin II receptor. *Hypertension* 24: 523–527, 1994.
89. **Kalra D, Sivasubramanian N, Mann DL.** Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. *Circulation* 105: 2198–2205, 2002.

90. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. *J Hypertens* 9: 17–22, 1991.
91. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. *Biochem Biophys Res Commun* 236: 622–625, 1997.
92. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, Lefkowitz RJ. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. *Proc Natl Acad Sci USA* 102: 1442–1447, 2005.
93. Kim S, Izumi Y, Yano M, Hamaguchi A, Miura K, Yamanaka S, Miyazaki H, Iwao H. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. *Circulation* 97: 1731–1737, 1998.
94. Kim S, Murakami T, Izumi Y, Yano M, Miura K, Yamanaka S, Iwao H. Extracellular signal-regulated kinase and c-Jun NH₂-terminal kinase activities are continuously and differentially increased in aorta of hypertensive rats. *Biochem Biophys Res Commun* 236: 199–204, 1997.
95. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. *Hypertension* 25: 1252–1259, 1995.
96. Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. *Arterioscler Thromb Vasc Biol* 20: 2539–2545, 2000.
97. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 19: 1623–1629, 1999.
98. Kudoh S, Komuro I, Mizuno T, Yamazaki T, Zou Y, Shiojima I, Takekoshi N, Yazaki Y. Angiotensin II stimulates c-Jun NH₂-terminal kinase in cultured cardiac myocytes of neonatal rats. *Circ Res* 80: 139–146, 1997.
99. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. *J Hypertens* 22: 2253–2261, 2004.
100. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. *Physiol Rev* 81: 807–869, 2001.
101. Landon EJ, Inagami T. Beyond the G protein: the saga of the type 2 angiotensin II receptor. *Arterioscler Thromb Vasc Biol* 25: 15–16, 2005.
102. Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, Griendling KK. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. *Mol Pharmacol* 48: 601–609, 1995.
103. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. *Circ Res* 88: 888–894, 2001.
104. Leduc I, Meloche S. Angiotensin II stimulates tyrosine phosphorylation of the focal adhesion-associated protein paxillin in aortic smooth muscle cells. *J Biol Chem* 270: 4401–4404, 1995.
105. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. *J Biol Chem* 273: 18677–18680, 1998.
106. Li C, Hu Y, Sturm G, Wick G, Xu Q. Ras/Rac-dependent activation of p38 mitogen-activated protein kinases in smooth muscle cells stimulated by cyclic strain stress. *Arterioscler Thromb Vasc Biol* 20: E1–E9, 2000.
107. Li DY, Zhang YC, Phillips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. *Circ Res* 84: 1043–1049, 1999.
108. Liao DF, Duff JL, Daum G, Pelech SL, Berk BC. Angiotensin II stimulates MAP kinase kinase activity in vascular smooth muscle cells. Role of Raf. *Circ Res* 79: 1007–1014, 1996.
109. Liao DF, Monia B, Dean N, Berk BC. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. *J Biol Chem* 272: 6146–6150, 1997.
110. Libby P, Lee RT. Matrix matters. *Circulation* 102: 1874–1876, 2000.
111. Lim SY, Kim YS, Ahn Y, Jeong MH, Hong MH, Joo SY, Nam KI, Cho JG, Kang PM, Park JC. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. *Cardiovasc Res* 70: 530–542, 2006.
112. Linseman DA, Benjamin CW, Jones DA. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. *J Biol Chem* 270: 12563–12568, 1995.
113. Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. *Eur Heart J* 24: 883–896, 2003.
114. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. *Circ Res* 90: 1259–1266, 2002.
115. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ. Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. *Hypertension* 33: 1013–1019, 1999.
116. Luft FC. Present status of genetic mechanisms in hypertension. *Med Clin North Am* 88: 1–18, vii, 2004.
117. Madamanchi NR, Li S, Patterson C, Runge MS. Reactive oxygen species regulate heat-shock protein 70 via the JAK/STAT pathway. *Arterioscler Thromb Vasc Biol* 21: 321–326, 2001.
118. Marrero MB, Fulton D, Stepp D, Stern DM. Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. *Arterioscler Thromb Vasc Biol* 24: 2009–2013, 2004.
119. Marrero MB, Schieffer B, Paxton WG, Heerd L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. *Nature* 375: 247–250, 1995.
120. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. *Am J Physiol Cell Physiol* 275: C1216–C1223, 1998.
121. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. *J Clin Invest* 92: 1866–1874, 1993.
122. Matsubara H, Moriguchi Y, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Uchiyama-Tanaka Y, Fujiyama S, Koyama Y, Nose-Fujiyama A, Iba S, Tateishi E, Iwasaka T. Transactivation of EGF receptor induced by angiotensin II regulates fibronectin and TGF-beta gene expression via transcriptional and post-transcriptional mechanisms. *Mol Cell Biochem* 212: 187–201, 2000.
123. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. *J Biol Chem* 280: 26592–26599, 2005.
124. Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H, Saruta T. Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. *Hypertension* 36: 845–850, 2000.
125. Moriguchi Y, Matsubara H, Mori Y, Murasawa S, Masaki H, Maruyama K, Tsutsumi Y, Shibasaki Y, Tanaka Y, Nakajima T, Oda K, Iwasaka T. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-beta synthesis via transcriptional and posttranscriptional mechanisms. *Circ Res* 84: 1073–1084, 1999.
126. Motley ED, Eguchi K, Gardner C, Hicks AL, Reynolds CM, Frank GD, Mifune M, Ohba M, Eguchi S. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. *Hypertension* 41: 775–780, 2003.
127. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. *J Biol Chem* 268: 24539–24542, 1993.
128. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. *Hypertension* 27: 760–765, 1996.
129. Natarajan R, Scott S, Bai W, Yerneni KK, Nadler J. Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. *Hypertension* 33: 378–384, 1999.
130. Nguyen G, Delarue F, Burckle C, Bouzahir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. *J Clin Invest* 109: 1417–1427, 2002.

131. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. *Circulation* 100: 2131–2134, 1999.
132. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Scholkens BA, Bohm M. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. *Am J Physiol Heart Circ Physiol* 272: H2701–H2707, 1997.
133. Nickenig G, Sachinidis A, Ko Y, Vetter H. Regulation of angiotensin AT1 receptor gene expression during cell growth of vascular smooth muscle cells. *Eur J Pharmacol* 297: 307–312, 1996.
134. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. *Circulation* 95: 473–478, 1997.
135. Nickenig G, Strehlow K, Wassmann S, Baumer AT, Albory K, Sauer H, Bohm M. Differential effects of estrogen and progesterone on AT₁ receptor gene expression in vascular smooth muscle cells. *Circulation* 102: 1828–1833, 2000.
136. Nishida M, Tanabe S, Maruyama Y, Mangmool S, Urayama K, Nagamatsu Y, Takagahara S, Turner JH, Kozasa T, Kobayashi H, Sato Y, Kawanishi T, Inoue R, Nagao T, Kurose H. G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH₂-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. *J Biol Chem* 280: 18434–18441, 2005.
137. Nishimura K, Li W, Hoshino Y, Kadohama T, Asada H, Ohgi S, Sumpio BE. Role of AKT in cyclic strain-induced endothelial cell proliferation and survival. *Am J Physiol Cell Physiol* 290: C812–C821, 2006.
138. Nosadini R, Tonolo G. The role of the renin angiotensin hormonal system in the metabolic syndrome and type 2 diabetes. *Nutr Metab Cardiovasc Dis* 14: 88–93, 2004.
139. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. *Hypertension* 40: 872–879, 2002.
140. Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. *Am J Physiol Cell Physiol* 291: C1–C10, 2006.
141. Ohtsu H, Frank GD, Utsunomiya H, Eguchi S. Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. *Antioxid Redox Signal* 7: 1315–1326, 2005.
142. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, Kim-Mitsuyama S, Takuwa Y, Sasaki T, Rothstein JD, Suzuki H, Nakashima H, Woolfolk EA, Motley ED, Eguchi S. Signal-crosstalk between Rho/ROCK and c-Jun NH₂-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. *Arterioscler Thromb Vasc Biol* 25: 1831–1836, 2005.
143. Ohyama K, Yamano Y, Sano T, Nakagomi Y, Hamakubo T, Morishima I, Inagami T. Disulfide bridges in extracellular domains of angiotensin II receptor type IA. *Regul Pept* 57: 141–147, 1995.
144. Okuda M, Kawahara Y, Nakayama I, Hoshijima M, Yokoyama M. Angiotensin II transduces its signal to focal adhesions via angiotensin II type 1 receptors in vascular smooth muscle cells. *FEBS Lett* 368: 343–347, 1995.
145. Oppermann M, Freedman NJ, Alexander RW, Lefkowitz RJ. Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C. *J Biol Chem* 271: 13266–13272, 1996.
146. Ottensmeyer FP, Beniac DR, Luo RZ, Yip CC. Mechanism of transmembrane signaling: insulin binding and the insulin receptor. *Biochemistry* 39: 12103–12112, 2000.
147. Papaiahgari S, Zhang Q, Kleeberger SR, Cho HY, Reddy SP. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. *Antioxid Redox Signal* 8: 43–52, 2006.
148. Patiag D, Qu X, Gray S, Idris I, Wilkes M, Seale JP, Donnelly R. Possible interactions between angiotensin II and insulin: effects on glucose and lipid metabolism in vivo and in vitro. *J Endocrinol* 167: 525–531, 2000.
149. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. *Circulation* 81: 1161–1172, 1990.
150. Polte TR, Naftilan AJ, Hanks SK. Focal adhesion kinase is abundant in developing blood vessels and elevation of its phosphotyrosine content in vascular smooth muscle cells is a rapid response to angiotensin II. *J Cell Biochem* 55: 106–119, 1994.
151. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. *Nature* 402: 884–888, 1999.
152. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. *Arterioscler Thromb Vasc Biol* 20: 645–651, 2000.
153. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griending KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest* 97: 1916–1923, 1996.
154. Rocic P, Govindarajan G, Sabri A, Lucchesi PA. A role for PYK2 in regulation of ERK1/2 MAP kinases and PI 3-kinase by ANG II in vascular smooth muscle. *Am J Physiol Cell Physiol* 280: C90–C99, 2001.
155. Rocic P, Jo H, Lucchesi PA. A role for PYK2 in ANG II-dependent regulation of the PHAS-1-eIF4E complex by multiple signaling cascades in vascular smooth muscle. *Am J Physiol Cell Physiol* 285: C1437–C1444, 2003.
156. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. *Am J Physiol Heart Circ Physiol* 250: H822–H827, 1986.
157. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. *Hypertension* 38: 1382–1387, 2001.
158. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT₁ and AT₂ in vascular smooth muscle cells: molecular mechanisms. *Circ Res* 86: 1266–1272, 2000.
159. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR-(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. *Hypertension* 43: 661–666, 2004.
160. Sabe H, Hamaguchi M, Hanafusa H. Cell to substratum adhesion is involved in v-Src-induced cellular protein tyrosine phosphorylation: implication for the adhesion-regulated protein tyrosine phosphatase activity. *Oncogene* 14: 1779–1788, 1997.
161. Sabri A, Govindarajan G, Griffin TM, Byron KL, Samarel AM, Lucchesi PA. Calcium- and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle. *Circ Res* 83: 841–851, 1998.
162. Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. *Circ Res* 96: 1064–1071, 2005.
163. Salmeen A, Barford D. Functions and mechanisms of redox regulation of cysteine-based phosphatases. *Antioxid Redox Signal* 7: 560–577, 2005.
164. Sarkis A, Lopez B, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. *Curr Opin Nephrol Hypertens* 13: 205–214, 2004.
165. Sasamura H, Shimizu-Hirota R, Nakaya H, Saruta T. Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats. *Hypertens Res* 24: 165–172, 2001.
166. Schena M, Mulatero P, Schiavone D, Mengozzi G, Tesio L, Chian-ducci L, Veglio F. Vasoactive hormones induce nitric oxide synthase mRNA expression and nitric oxide production in human endothelial cells and monocytes. *Am J Hypertens* 12: 388–397, 1999.
167. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. *Circulation* 101: 1372–1378, 2000.
168. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. *Circulation* 101: 1653–1659, 2000.

169. Schmitz U, Ishida T, Ishida M, Surapisitchat J, Hasham MI, Pelech S, Berk BC. Angiotensin II stimulates p21-activated kinase in vascular smooth muscle cells: role in activation of JNK. *Circ Res* 82: 1272–1278, 1998.
170. Seachrist JL, Laporte SA, Dale LB, Babwah AV, Caron MG, Anborgh PH, Ferguson SS. Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion. *J Biol Chem* 277: 679–685, 2002.
171. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, Nakano T. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. *Circ Res* 92: 411–418, 2003.
172. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. *FASEB J* 10: 709–720, 1996.
173. Senbonmatsu T, Saito T, Landon EJ, Watanabe O, Price E Jr, Roberts RL, Imboden H, Fitzgerald TG, Gaffney FA, Inagami T. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. *EMBO J* 22: 6471–6482, 2003.
174. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. *Circ Res* 91: 406–413, 2002.
175. Shanmugam S, Corvol P, Gasc JM. Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat. *Hypertension* 28: 91–97, 1996.
176. Shimizu-Hirota R, Sasamura H, Mifune M, Nakaya H, Kuroda M, Hayashi M, Saruta T. Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. *J Am Soc Nephrol* 12: 2609–2615, 2001.
177. Shin HM, Je HD, Gallant C, Tao TC, Hartshorne DJ, Ito M, Morgan KG. Differential association and localization of myosin phosphatase subunits during agonist-induced signal transduction in smooth muscle. *Circ Res* 90: 546–553, 2002.
178. Somsel Rodman J, and Wandinger-Ness A. Rab GTPases coordinate endocytosis. *J Cell Sci* 113: 183–192, 2000.
179. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de Leeuw PW. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. *Hypertension* 36: 411–416, 2000.
180. Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). *Int J Mol Med* 9: 85–89, 2002.
181. Stokoe D, Engel K, Campbell DG, Cohen P, Gaestel M. Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. *FEBS Lett* 313: 307–313, 1992.
182. Sugden PH, Clerk A. Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. *Cell Signal* 9: 337–351, 1997.
183. Suzuki H, Motley ED, Frank GD, Utsunomiya H, Eguchi S. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. *Curr Med Chem Cardiovasc Hematol Agents* 3: 305–322, 2005.
184. Takayanagi R, Ohnaka K, Sakai Y, Nakao R, Yanase T, Haji M, Inagami T, Furuta H, Gou DF, Nakamuta M, et al. Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. *Biochem Biophys Res Commun* 183: 910–916, 1992.
185. Takeda K, Ichiki T, Funakoshi Y, Ito K, Takeshita A. Downregulation of angiotensin II type 1 receptor by all-trans retinoic acid in vascular smooth muscle cells. *Hypertension* 35: 297–302, 2000.
186. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. *Hypertension* 42: 1075–1081, 2003.
187. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. *Arterioscler Thromb Vasc Biol* 25: 1142–1147, 2005.
188. Taniyama Y, Ushio-Fukai M, Hitomi H, Rocic P, Kingsley MJ, Pfahnl C, Weber DS, Alexander RW, Griendling KK. Role of p38 MAPK and MAPKAP-2 in angiotensin II-induced Akt activation in vascular smooth muscle cells. *Am J Physiol Cell Physiol* 287: C494–C499, 2004.
189. Taniyama Y, Weber DS, Rocic P, Hilenski L, Akers ML, Park J, Hemmings BA, Alexander RW, Griendling KK. Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal adhesions. *Mol Cell Biol* 23: 8019–8029, 2003.
190. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. *EMBO Rep* 2: 222–228, 2001.
191. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells—implications in cardiovascular disease. *Braz J Med Biol Res* 37: 1263–1273, 2004.
192. Touyz RM, He G, Deng LY, Schiffrin EL. Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. *Circulation* 99: 392–399, 1999.
193. Touyz RM, He G, El Mabrouk M, Schiffrin EL. p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. *Hypertension* 37: 574–580, 2001.
194. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. *Pharmacol Rev* 52: 639–672, 2000.
195. Touyz RM, Yao G, Quinn MT, Pagano PJ, Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. *Arterioscler Thromb Vasc Biol* 25: 512–518, 2005.
196. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. *J Hypertens* 22: 1141–1149, 2004.
197. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Mura-sawa S, Kijima K, Maruyama K, Masaki H, Moriguchi Y, Shibasaki Y, Kamihata H, Inada M, Iwasaka T. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. *Circ Res* 83: 1035–1046, 1998.
198. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. *Nature* 389: 990–994, 1997.
199. Ullian ME, Raymond JR, Willingham MC, Paul RV. Regulation of vascular angiotensin II receptors by EGF. *Am J Physiol Cell Physiol* 273: C1241–C1249, 1997.
200. Ushio-Fukai M, Alexander RW, Akers M, Lyons PR, Lassegue B, Griendling KK. Angiotensin II receptor coupling to phospholipase D is mediated by the betagamma subunits of heterotrimeric G proteins in vascular smooth muscle cells. *Mol Pharmacol* 55: 142–149, 1999.
201. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. *J Biol Chem* 274: 22699–22704, 1999.
202. Ushio-Fukai M, Griendling KK, Akers M, Lyons PR, Alexander RW. Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. *J Biol Chem* 273: 19772–19777, 1998.
203. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 21: 489–495, 2001.
204. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. *J Biol Chem* 271: 23317–23321, 1996.
205. Ushio-Fukai M, Zuo L, Ikeda S, Tojo T, Patrushev NA, Alexander RW. cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. *Circ Res* 97: 829–836, 2005.
206. Vallega GA, Canessa ML, Berk BC, Brock TA, Alexander RW. Vascular smooth muscle Na⁺-H⁺ exchanger kinetics and its activation by angiotensin II. *Am J Physiol Cell Physiol* 254: C751–C758, 1988.
207. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJ, van Gilst WH. Angiotensin II type 1 receptor A1166C gene

- polymorphism is associated with an increased response to angiotensin II in human arteries. *Hypertension* 35: 717–721, 2000.
208. **Velarde V, Jenkins AJ, Christopher J, Lyons TJ, Jaffa AA.** Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells. *J Appl Physiol* 91: 1412–1420, 2001.
 209. **Viswanathan M, Stromberg C, Seltzer A, Saavedra JM.** Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta. *J Clin Invest* 90: 1707–1712, 1992.
 210. **Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G.** Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. *Circulation* 110: 3062–3067, 2004.
 211. **Weiss D, Kools JJ, Taylor WR.** Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. *Circulation* 103: 448–454, 2001.
 212. **Wierzbicki AS, Lambert-Hammill M, Lumb PJ, Crook MA.** Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia. *Hypertension* 36: 808–812, 2000.
 213. **Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W.** Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. *Circ Res* 80: 219–227, 1997.
 214. **Wu G, Zhao G, He Y.** Distinct pathways for the trafficking of angiotensin II and adrenergic receptors from the endoplasmic reticulum to the cell surface: Rab1-independent transport of a G protein-coupled receptor. *J Biol Chem* 278: 47062–47069, 2003.
 215. **Wu S, Gao J, Ohlemeyer C, Roos D, Niessen H, Kottgen E, Gessner R.** Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. *Free Radic Biol Med* 39: 1601–1610, 2005.
 216. **Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE.** Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 19: 73–82, 1999.
 217. **Yan C, Kim D, Aizawa T, Berk BC.** Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. *Arterioscler Thromb Vasc Biol* 23: 26–36, 2003.
 218. **Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, Mehta JL.** Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. *Arterioscler Thromb Vasc Biol* 18: 1433–1439, 1998.
 219. **Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J.** Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. *Circulation* 99: 1370–1378, 1999.
 220. **Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.** Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 342: 145–153, 2000.
 221. **Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK.** Role of NADH/NADPH oxidase-derived H₂O₂ in angiotensin II-induced vascular hypertrophy. *Hypertension* 32: 488–495, 1998.
 222. **Zeng C, Luo Y, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA.** Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats. *Hypertension* 42: 787–792, 2003.
 223. **Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H.** Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. *Arterioscler Thromb Vasc Biol* 23: 795–801, 2003.
 224. **Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW.** Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. *Arterioscler Thromb Vasc Biol* 25: 1824–1830, 2005.

